India to United Kingdom: Ertapenem Export Trade Route

The India to United Kingdom Ertapenem corridor is one of India's established pharmaceutical export routes, with 11 shipments documented worth a combined $1.4M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's ertapenem manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $129.3K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 72% of all shipments, consistent with ertapenem's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 32 days port-to-port. The route has recorded an annual growth rate of 29.0%, placing it at rank #6 among India's top ertapenem export destinations globally.

On the import side, key buyers of Indian ertapenem in United Kingdom include MILPHARM LIMITED, ALLOGA UK,, MILPHARM LIMITED ALLOGA UKAMBER PARK, MILPHARM LIMITED, ALLOGA UK and 3 others. MILPHARM LIMITED, ALLOGA UK, is the single largest importer with 4 shipments valued at $567.8K USD.

India's ertapenem exports to United Kingdom are driven primarily by a handful of large-scale manufacturers. EUGIA PHARMA SPECIALITIES LIMITED with 10 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in United Kingdom benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, VEA IMPEX I PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $129.3K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as ertapenem for injection 1g vial ertapenem milpharm 1g powder for conce for solution bt 2ei25074a mfg 3 25 exp 2 27 and ertapenem for injection1g/vial(ertapenemmilpharm1g pwdr for con.for solution for infusion)bt#2ei25036a,mfg#2/25,ex#1/27, suggesting that buyers in United Kingdom tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, MILPHARM LIMITED, ALLOGA UK, is the largest importer with 4 shipments worth $567.8K USD — representing 40% of all ertapenem imports from India on this route. A total of 6 buyers are active on this corridor.